US Patent 11357779 G1T38 superior dosage regimes
Patent 11357779 was granted and assigned to G1 Therapeutics on June, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 10 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 22 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 28 Mar, 2023
Golden AI
Edits on 27 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113577790
Date of Patent
June 14, 2022
0Patent Application Number
169240330
Date Filed
July 8, 2020
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 22 Mar, 2023
Golden AI
Infobox
Edits on 28 Sep, 2022
Golden AI
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113577790
Date of Patent
June 14, 2022
0Patent Application Number
169240330
Date Filed
July 8, 2020
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Golden AI
Infobox
Golden AI
Infobox
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+17 properties)
Article (+242 characters)
US Patent 11357779 G1T38 superior dosage regimes
Article
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11357779
Date of patent
June 14, 2022
Patent application number
16924033
Date Filed
July 8, 2020
Patent citations
Patent primary examiner
CPC Code
Find more entities like US Patent 11357779 G1T38 superior dosage regimes
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.